Literature DB >> 11226640

Glial cell line-derived neurotrophic factor in the substantia nigra from control and parkinsonian brains.

M Mogi1, A Togari, T Kondo, Y Mizuno, O Kogure, S Kuno, H Ichinose, T Nagatsu.   

Abstract

Glial cell line-derived neurotrophic factor (GDNF) was measured for the first time in the brain (substantia nigra, caudate nucleus, putamen, cerebellum, and frontal cortex) from control and parkinsonian patients by highly sensitive sandwich enzyme-linked immunosorbent assay. In both groups, the levels of GDNF in the various brain regions were lower (pg/mg protein) than those of brain-derived growth factor (ng/mg order), and were significantly higher in the nigro-striatal dopaminergic regions (substantia nigra, caudate nucleus, putamen) than in the cerebellum and frontal cortex (P < 0.05). However, the content of GDNF in the dopaminergic regions showed no significant difference between parkinsonian and control patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11226640     DOI: 10.1016/s0304-3940(01)01577-4

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  14 in total

1.  Transgenic expression of human glial cell line-derived neurotrophic factor from integration-deficient lentiviral vectors is neuroprotective in a rodent model of Parkinson's disease.

Authors:  Ngoc B Lu-Nguyen; Martin Broadstock; Maximilian G Schliesser; Cynthia C Bartholomae; Christof von Kalle; Manfred Schmidt; Rafael J Yáñez-Muñoz
Journal:  Hum Gene Ther       Date:  2014-04-15       Impact factor: 5.695

2.  Impact of methamphetamine on dopamine neurons in primates is dependent on age: implications for development of Parkinson's disease.

Authors:  B A Morrow; R H Roth; D E Redmond; J D Elsworth
Journal:  Neuroscience       Date:  2011-06-01       Impact factor: 3.590

3.  Efficient gene therapy for Parkinson's disease using astrocytes as hosts for localized neurotrophic factor delivery.

Authors:  Anja Drinkut; Yuliya Tereshchenko; Jörg B Schulz; Mathias Bähr; Sebastian Kügler
Journal:  Mol Ther       Date:  2011-11-15       Impact factor: 11.454

Review 4.  Parkinson's disease: an update on pathogenesis and treatment.

Authors:  Tom Foltynie; Joshua Kahan
Journal:  J Neurol       Date:  2013-04-16       Impact factor: 4.849

5.  The nigrostriatal dopamine system of aging GFRalpha-1 heterozygous mice: neurochemistry, morphology and behavior.

Authors:  Vandana Zaman; Heather A Boger; Ann-Charlotte Granholm; Baerbel Rohrer; Alfred Moore; Mona Buhusi; Greg A Gerhardt; Barry J Hoffer; Lawrence D Middaugh
Journal:  Eur J Neurosci       Date:  2008-10       Impact factor: 3.386

Review 6.  Treatment of Parkinson's disease with trophic factors.

Authors:  Amie L Peterson; John G Nutt
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

7.  Imaging of peripheral benzodiazepine receptor expression as biomarkers of detrimental versus beneficial glial responses in mouse models of Alzheimer's and other CNS pathologies.

Authors:  Bin Ji; Jun Maeda; Makoto Sawada; Maiko Ono; Takashi Okauchi; Motoki Inaji; Ming-Rong Zhang; Kazutoshi Suzuki; Kiyoshi Ando; Matthias Staufenbiel; John Q Trojanowski; Virginia M Y Lee; Makoto Higuchi; Tetsuya Suhara
Journal:  J Neurosci       Date:  2008-11-19       Impact factor: 6.167

8.  Astrocytes as a source for extracellular matrix molecules and cytokines.

Authors:  Stefan Wiese; Michael Karus; Andreas Faissner
Journal:  Front Pharmacol       Date:  2012-06-26       Impact factor: 5.810

Review 9.  Neurotrophic factors in Alzheimer's and Parkinson's diseases: implications for pathogenesis and therapy.

Authors:  Tuane Bazanella Sampaio; Anne Suely Savall; Maria Eduarda Ziani Gutierrez; Simone Pinton
Journal:  Neural Regen Res       Date:  2017-04       Impact factor: 5.135

Review 10.  GDNF-based therapies, GDNF-producing interneurons, and trophic support of the dopaminergic nigrostriatal pathway. Implications for Parkinson's disease.

Authors:  Xavier d'Anglemont de Tassigny; Alberto Pascual; José López-Barneo
Journal:  Front Neuroanat       Date:  2015-02-13       Impact factor: 3.856

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.